298 related articles for article (PubMed ID: 16310536)
1. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
Colhoun H
Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
[No Abstract] [Full Text] [Related]
2. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
3. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Bilz S
Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
[No Abstract] [Full Text] [Related]
5. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Pérez A
Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
[No Abstract] [Full Text] [Related]
6. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
Armitage J; Collins R
Heart; 2000 Oct; 84(4):357-60. PubMed ID: 10995396
[No Abstract] [Full Text] [Related]
7. A case report of a diabetic woman with very low HDL cholesterol.
Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
[No Abstract] [Full Text] [Related]
8. Combination lipid therapy in type 2 diabetes.
Perkins WJ
N Engl J Med; 2010 Aug; 363(7):694; author reply 694-5. PubMed ID: 20842773
[No Abstract] [Full Text] [Related]
9. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
12. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
13. All at sea: new lipid-lowering drug trials continue to disappoint.
Wierzbicki AS
Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438
[No Abstract] [Full Text] [Related]
14. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
[TBL] [Abstract][Full Text] [Related]
15. Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
Al-Waili K; Al-Zakwani I; Al-Dughaishi T; Baneerje Y; Al-Sabti H; Al-Hashmi K; Farhan H; Habsi KA; Al-Hinai AT; Al-Rasadi K
Angiology; 2014 May; 65(5):430-5. PubMed ID: 23564019
[TBL] [Abstract][Full Text] [Related]
16. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
17. The work-up for mixed hyperlipidemia: a case study.
Rehman HU
J Fam Pract; 2012 Mar; 61(3):133-6. PubMed ID: 22393551
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
19. Retinopathy progression in type 2 diabetes.
Baum SJ
N Engl J Med; 2010 Nov; 363(22):2172; author reply 2173-4. PubMed ID: 21105808
[No Abstract] [Full Text] [Related]
20. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
Båvenholm P; Attvall S; Nilsson PM
Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
